Received Aug 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y015180 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y012776 | — |
No symptoms reported. No additional AE; patient was inadvertently administered a second dose of GARDASIL 9 at a shorter interval than recommended; This spontaneous report was received from a Physician Assistant (reported as medical assistant) and refers to a 14-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On 31-JUL-2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), prefilled syringe, 0.5 mL/dose (lot number Y015180 has been verified to be valid for Human Papillomavirus 9-valent Vaccine, Recombinant [GARDASIL 9], expiration date 28-JAN-2027). On 05-Aug-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), prefilled syringe, 0.5 mL/dose (lot number Y012776 has been verified to be valid for Human Papillomavirus 9-valent Vaccine, Recombinant [GARDASIL 9], expiration date 08-JAN-2027); both doses were administered as prophylaxis (route of administration, dose form and anatomical site of injection were not reported for any of the vaccines). The second dose was administered at a shorter interval than recommended (Inappropriate schedule of product administration). No symptoms or additional adverse event were reported for the patient.